Controlled Trial of 3 4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS)
The overall purpose is to provide children access to 3,4-DAP, which is not currently approved by the FDA for use in the United States.
This study is designed to provide 3,4-DAP to patients with Lambert-Eaton Myasthenic Syndrome (LEMS) in attempt to improve their quality of life.
- IRB Number: 1010002406
- Research Study Identifier: TX1285
- Principal Investigator: Robert Pascuzzi, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required